Gene Editing?CRISPR-Cas9 gene editing offers substantial improvements over previous gene editing technologies in terms of ease of use, speed, efficacy, and cost. Not surprisingly, CRISPR-Cas9 editing has taken biomedical science by storm. While the technology is relatively simple in handling at the level of basic research, the use of CRISPR genome editing in therapeutical applications poses a bunch of
analytical challenges.
AstraZeneca unloads respiratory drugs to Covis
Latest NewsLuxembourg-headquartered Covis is taking two COPD drugs off AstraZeneca’s hands in a US$270m deal.
Benefits of 5000 L single-use bioreactors
Sponsored PublicationsThis white paper focuses on a new generation of single-use bioreactors, built to deliver high-volume performance and how they address many issue.
IZB start-up: Eisbach Bio GmbH
Sponsored PublicationsEisbach Bio GmbH is a spin-off of the Ludwig Maximilian University in Munich. The company is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
Agomab Therapeutics to acquire Origo Biopharma
Latest NewsBelgian Agomab Therapeutics NV is expanding its European footprint by acuiring Barcelona-based fibrosis therapy specialist Origo Biopharma.
Evotec goes for massive IPO on Nasdaq
Latest NewsGerman drug discovery company Evotec plans to raise US$576m on the US-American stock exchange Nasdaq to finance extensive investments.
€40m for Treg starver start-up
Latest NewsInstitut Curie spin-off Egle Therapeutics has raised €40m in a Series A financing. The company will use the funds to develop First-In-Class T-regulatory cells therapies based on Treg starvers.
From make-up to jet fuel: Breakthrough for Global Bioenergies
Latest NewsThe French company has taken big steps to scale up its process for converting plant-based feedstocks into isobutene, bringing affordable aviation biofuels into reach.
Analytical demand of CRISPR gene therapies
BackgroundGene Editing?CRISPR-Cas9 gene editing offers substantial improvements over previous gene editing technologies in terms of ease of use, speed, efficacy, and cost. Not surprisingly, CRISPR-Cas9 editing has taken biomedical science by storm. While the technology is relatively simple in handling at the level of basic research, the use of CRISPR genome editing in therapeutical applications poses a bunch of
analytical challenges.
Sofinnova Capital X Fund closed at €472m
Latest NewsParis-based life sciences venture capital firm Sofinnova Partners has closed the largest early-stage healthcare VC fund in Europe.
Medical cold chain for gene and cell therapies
BackgroundThe medical cold chain is the network of refrigerators, freezers, and transport solutions tasked to always keep samples and specimens at their intended temperatures. When it comes to cell and gene research and therapy, temperature requirements can be demanding, requiring the deployment of specialised refrigeration products. With its refrigeration solutions, B Medical Systems can help in always keeping your specimens safe.